At the 19th Asia-Pacific German Business Conference (APK 2026) in Seoul, Shashank Deshpande, Chairman of the Board of Managing Directors at Boehringer Ingelheim, highlighted Korea as a pivotal global drug development partner rather than merely a sales market. In an interview with The Herald Business, he emphasized the company's commitment to connecting Korea’s scientific innovation with its global R&D network.
Boehringer Ingelheim is actively expanding its footprint in Korea through initiatives such as its ADC candidate co-development with Aimed Bio, an expanded alliance with Yuhan, venture investments in startups, and prospective collaborations with advanced Korean AI firms to reduce clinical trial failure rates. Deshpande concluded that Korean healthcare innovation is well-positioned to benefit patients worldwide through these long-term strategic partnerships.
The full article is available via the link.